No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
RGNX250117C10000
- 0.33
- 0.000.00%
15min DelayTrading Dec 18 15:12 ET
0.00High0.00Low
0.00Open0.33Pre Close0 Volume202 Open Interest10.00Strike Price0.00Turnover141.52%IV39.78%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.33Extrinsic Value100Contract SizeAmericanOptions Type0.2559Delta0.1187Gamma21.11Leverage Ratio-0.0175Theta0.0010Rho5.40Eff Leverage0.0062Vega
Intraday
- 5D
- Daily
News
PepGen Stock Craters 35% on FDA Clinical Hold
RBC Capital Reiterates Outperform on Regenxbio, Maintains $35 Price Target
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
Express News | Regenxbio Inc - to Offer and Sell Shares up to $150 Million
Express News | Regenxbio Inc - on Dec 9, Co Enters Sales Agreement With Leerink Partners
Apollo Global Management, Workday to Join S&P 500